topotecan

P1, N=24, Not yet recruiting, Nerviano Medical Sciences

P3, N=107, Completed, St. Jude Children's Research Hospital | Active, not recruiting --> Completed

P1/2, N=62, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Oct 2025 --> Dec 2024

P1, N=1, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2025 --> Jul 2024

P1, N=60, Recruiting, National Cancer Institute (NCI) | Suspended --> Recruiting | Trial completion date: Apr 2025 --> Apr 2027 | Trial primary completion date: Apr 2025 --> Apr 2027

Thus, this work aims to evaluate the performance of the compounds Acriflavine, Resveratrol, Topotecan, and RNA interference (siRNA) as HIF inhibitors as well as a therapeutic approach...Furthermore, treatments performed with siRNAs effectively inhibited gene expression of HIFs in HN13 and FaDu (carcinoma of the pharynx) cell lines. Considering the role of hypoxia and HIFs in tumor aggressiveness; the present study shows the potential of the evaluated compounds as a therapeutic use for the prevention of tumor progression in head and neck cancer.

P3, N=84, Completed, Hospital JP Garrahan | Active, not recruiting --> Completed | N=200 --> 84 | Trial completion date: Dec 2025 --> Mar 2025

P3, N=110, Recruiting, Children's Oncology Group | Not yet recruiting --> Recruiting | Initiation date: Mar 2025 --> Jun 2025

P3, N=300, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P1, N=90, Recruiting, Boehringer Ingelheim | N=65 --> 90 | Trial completion date: Nov 2026 --> Apr 2027 | Trial primary completion date: Jan 2026 --> Jun 2026

P1, N=25, Completed, City of Hope Medical Center | Active, not recruiting --> Completed

P3, N=695, Recruiting, Gilead Sciences | Not yet recruiting --> Recruiting

P3, N=502, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Aug 2025 --> May 2026

Cell viability of drug-resistant cells upon QB1561 alone or combined with topotecan and mitoxantrone was determined by MTS assay. QB1561 was effective for the treatment of MDR in drug-resistant cancer cells. Its further evaluation could be useful for the design and development of more gold-based anticancer drugs.

Docetaxel (DTX) and Cabazitaxel (CTX) are two of the most extensively used drugs for metastatic castration-resistant prostate cancer (mCRPC). Since taxanes, DTX and CTX, are ineffective against RCaP cell line, we selected a topoisomerase I inhibitor, topotecan (TPT) as a replacement for taxanes. We screened the library of SB-FIs for synergy with TPT and identified 3 SB-FIs (L3, α-11 and α-4), exhibiting strong synergy, which could remarkably expand the therapeutic window of TPT.

P2, N=153, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Dec 2024 --> Dec 2025

Notably, combinations of IMGN853 with topotecan or the anti-VEGF-A antibody B20 significantly reduced tumor growth compared to IMGN853 alone, while no significant effect was observed with olaparib. Our findings indicate that IMGN853 induces autophagic cell death, which contributes to its tumor-inhibiting effects. The identification of these effective combination therapies and the mechanisms behind FOLR1-mediated autophagic cell death could facilitate further clinical development of IMGN853.

P3, N=468, Not yet recruiting, Hansoh BioMedical R&D Company

P2, N=110, Active, not recruiting, BioNTech SE | Recruiting --> Active, not recruiting

Treatment of refractory and relapse/progressive HR-NB is highly heterogeneous. We confirm a poor outcome, although certain epidemiological and treatment-related factors have prognostic value. Molecular profiling and inclusion in CTs should be improved.

P2, N=30, Recruiting, Targeted Therapy Technologies, LLC | Not yet recruiting --> Recruiting | Initiation date: Nov 2024 --> Feb 2025

P1, N=65, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=65, Recruiting, Boehringer Ingelheim | Trial completion date: Apr 2026 --> Nov 2026

P1, N=30, Completed, New Approaches to Neuroblastoma Therapy Consortium | Active, not recruiting --> Completed

P1, N=18, Active, not recruiting, New Approaches to Neuroblastoma Therapy Consortium | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

P3, N=300, Not yet recruiting, Jiangsu HengRui Medicine Co., Ltd.

P3, N=438, Recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=394, Not yet recruiting, Unity Health Toronto

LY3295668 erbumine had a manageable safety profile as monotherapy and in combination therapy. Although proof-of-concept clinical responses were observed, future studies with biomarker-selected populations and/or novel combinations may yield higher response rates with Aurora kinase A inhibition.

P2, N=50, Recruiting, Unity Health Toronto | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Feb 2025 --> Feb 2026

P3, N=695, Not yet recruiting, Gilead Sciences

These findings were also confirmed in a BCRP-expressing human breast cancer cell line (MCF-7/MXR), which was selected for resistance to Mitoxantrone. RSL3 also significantly increased Topotecan cytotoxicity. Our findings-demonstrating increased cytotoxicity of Adriamycin and Topotecan in P-gp- and BCRP-expressing cells-suggest that ferroptosis inducers may be highly valuable in combination with other chemotherapeutics to manage patients' cancer burden in the clinical setting.

P1/2, N=231, Recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2029 --> Jan 2028 | Trial primary completion date: Feb 2029 --> Oct 2027

P3, N=530, Recruiting, Genmab | Not yet recruiting --> Recruiting

P3, N=530, Not yet recruiting, Genmab | Trial completion date: Nov 2029 --> Apr 2028 | Trial primary completion date: Feb 2027 --> May 2027

P3, N=705, Active, not recruiting, PharmaMar | Recruiting --> Active, not recruiting

These findings suggest that factors beyond gene expression, such as spheroid architecture, cell-cell interactions, and drug penetration, contribute to the enhanced resistance observed in 3D cultures. These results highlight the importance of 3D cell culture models for a more accurate representation of tumour drug resistance mechanisms in ovarian cancer, providing valuable insights for therapeutic development.

P1/2, N=455, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Trial completion date: Aug 2027 --> Feb 2031 | Trial primary completion date: Aug 2027 --> Feb 2031

P1, N=99, Active, not recruiting, Children's Oncology Group | Trial completion date: Sep 2024 --> Sep 2025

P3, N=430, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd

P3, N=430, Not yet recruiting, Jiangsu Alphamab Biopharmaceuticals Co., Ltd

P1/2, N=38, Terminated, Hoffmann-La Roche | Completed --> Terminated; Study was terminated by the sponsor based on insufficient tolerability and efficacy to proceed beyond Part 1b.